|
NOTICE OF ALLOWANCE (NOA)
ISSUE DATE: Jun 4, 2019 |
U.S. Serial Number: 88271729
Mark: QUELMIA
Docket/Reference Number:
|
| No opposition was filed for this published application. The issue date of this NOA establishes the due date for the filing of
a Statement of Use (SOU) or a Request for Extension of Time to file a Statement of Use (Extension Request). WARNING: An SOU that meets all legal requirements must be filed before a registration
certificate can issue. Please read below for important information regarding the applicant's pending six (6) month deadline. |
| SIX (6)-MONTH DEADLINE: Applicant has six (6) MONTHS from the NOA issue date to file either: |
| - |
An SOU, if the applicant is using the mark in commerce (required even if the applicant was using the mark at the time of filing the
application, if use basis was not specified originally); OR |
| - |
An Extension Request, if the applicant is not yet using the mark in commerce. If an Extension Request is filed, a new request must
be filed every six (6) months until the SOU is filed. The applicant may file a total of five (5) extension requests. WARNING: An SOU may not be filed more than thirty-six
(36) months from when the NOA issued. The deadline for filing is always calculated from the issue date of the NOA. |
How to file SOU and/or Extension Request:
Use the Trademark Electronic Application System (TEAS). Do NOT reply to this e-mail, as e-mailed filings will NOT be processed. Both the SOU and Extension Request have many
legal requirements, including fees and verified statements; therefore, please use the USPTO forms available online at http://www.gov.uspto.report/trademarks-application-process/filing-online (under the "INTENT-TO-USE (ITU) FORMS" category) to avoid the possible omission of required information.
If you have questions about this notice, please contact the Trademark Assistance Center at 1-800-786-9199. |
| FAILURE TO FILE A REQUIRED DOCUMENT OUTLINED ABOVE DURING THE APPROPRIATE TIME PERIOD WILL RESULT IN THE ABANDONMENT OF THIS
APPLICATION. |
REVIEW APPLICATION INFORMATION FOR ACCURACY |
| Serial Number: |
88271729
|
| Mark: |
QUELMIA
|
| Docket/Reference Number: |
|
| Owner: |
Allergan Sales, LLC
5 Giralda Farms
Madison , NEW JERSEY 07940
|
| Correspondence Address: |
SUSAN J. HINCHEY
ALLERGAN, INC.
2525 DUPONT DRIVE
IRVINE, CA 92612
|
This application has the following bases, but not necessarily for all listed goods/services: |
|
Section 1(a): NO |
Section 1(b): YES |
Section 44(e): NO |
| GOODS/SERVICES BY INTERNATIONAL CLASS |
| 005 - |
Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and
conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective,
anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor
ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias , smooth muscle disorders, autonomic nerve disorders,
headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin
lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations ; Pharmaceutical
preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations
for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and
prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing
pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory
organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ
disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood
pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for
the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone
disorders or bone diseases; Antibiotics ; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical
preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical
preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system
diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia,
AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating
agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers,
rejuvenators, rehydrating creams, and lotions for the face and body -- FIRST USE DATE: NONE; -- USE IN COMMERCE DATE: NONE |
ALL OF THE GOODS/SERVICES IN EACH CLASS ARE LISTED.
|
| Appropriate Specimens for Goods and/or Services: A trademark specimen should be a label, tag, or container for the goods, or a
display associated with the goods. See TMEP §§904.03 et seq. A service mark specimen should be an advertisement, sign, brochure, website printout or other image that shows the mark used in the actual
sale or advertising of the services. See TMEP §§1301.04 et seq. For an instructional video on what is an appropriate trademark or service mark specimen for a good and/or service, click here. |
| Fraudulent statements may result in registration being cancelled: Applicants must ensure that statements made in filings to the
USPTO are accurate, as inaccuracies may result in the cancellation of any issued trademark registration. The lack of a bona fide intention to use the mark with ALL goods and/or services listed
in an application or the lack of actual use on all goods and/or services for which use is claimed could jeopardize the validity of the registration, possibly resulting in its
cancellation. |
| Additional information: For information on filing and maintenance requirements for U.S. trademark applications and registrations
and required fees, please consult the USPTO website at http://www.uspto.gov or call the Trademark Assistance Center at 1-800-786-9199. |
|